新型抗菌剂 PRF-119（一种重组嵌合噬菌体溶菌素）对金黄色葡萄球菌的体外活性。
In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin.
机构信息
University Hospital of Münster, Institute of Medical Microbiology, D-48149 Münster, Germany.
出版信息
Antimicrob Agents Chemother. 2011 Sep;55(9):4416-9. doi: 10.1128/AAC.00217-11. Epub 2011 Jul 11.
Abstract
Antistaphylococcal activity of the novel chimeric endolysin PRF-119 was evaluated with the microdilution method. The MIC(50) and MIC(90) of 398 methicillin-susceptible Staphylococcus aureus isolates were 0.098 μg/ml and 0.391 μg/ml, respectively (range, 0.024 to 0.780 μg/ml). Both the MIC(50) and MIC(90) values of 776 methicillin-resistant S. aureus isolates were 0.391 μg/ml (range, 0.024 to 1.563 μg/ml). All 192 clinical isolates of coagulase-negative staphylococci exhibited MIC values of >50 μg/ml. In conclusion, PRF-119 exhibited very good activity specifically against S. aureus.
摘要
采用微量稀释法评估了新型嵌合内溶素 PRF-119 的抗葡萄球菌活性。398 株甲氧西林敏感金黄色葡萄球菌分离株的 MIC50 和 MIC90 分别为 0.098μg/ml 和 0.391μg/ml（范围为 0.024 至 0.780μg/ml）。776 株耐甲氧西林金黄色葡萄球菌分离株的 MIC50 和 MIC90 值均为 0.391μg/ml（范围为 0.024 至 1.563μg/ml）。所有 192 株凝固酶阴性葡萄球菌的临床分离株 MIC 值均>50μg/ml。总之，PRF-119 对金黄色葡萄球菌具有非常好的活性。
相似文献
1
In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin.
Antimicrob Agents Chemother. 2011 Sep;55(9):4416-9. doi: 10.1128/AAC.00217-11. Epub 2011 Jul 11.
2
Bactericidal activity of bacteriophage endolysin HY-133 against Staphylococcus aureus in comparison to other antibiotics as determined by minimum bactericidal concentrations and time-kill analysis.
Diagn Microbiol Infect Dis. 2019 Apr;93(4):362-368. doi: 10.1016/j.diagmicrobio.2018.11.005. Epub 2018 Nov 20.
3
The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2551-3. doi: 10.1128/AAC.02859-15. Print 2016 Apr.
4
A Novel Chimeric Endolysin with Antibacterial Activity against Methicillin-Resistant .
Front Cell Infect Microbiol. 2017 Jun 30;7:290. doi: 10.3389/fcimb.2017.00290. eCollection 2017.
5
Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
Antimicrob Agents Chemother. 2013 Jul;57(7):3178-81. doi: 10.1128/AAC.00484-13. Epub 2013 Apr 29.
6
The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
FEMS Microbiol Lett. 2008 Oct;287(2):185-91. doi: 10.1111/j.1574-6968.2008.01308.x. Epub 2008 Aug 21.
7
Anti-staphylococcal lysin, LSVT-1701, activity: In vitro susceptibility of Staphylococcus aureus and coagulase-negative staphylococci (CoNS) clinical isolates from around the world collected from 2002 to 2019.
Diagn Microbiol Infect Dis. 2021 Nov;101(3):115471. doi: 10.1016/j.diagmicrobio.2021.115471. Epub 2021 Jun 26.
8
The Novel Phage-Derived Antimicrobial Agent HY-133 Is Active against Livestock-Associated Methicillin-Resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00385-18. Print 2018 Jul.
9
Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands.
Appl Environ Microbiol. 2012 Apr;78(7):2297-305. doi: 10.1128/AEM.07050-11. Epub 2012 Jan 27.
10
Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus.
Appl Environ Microbiol. 2007 Jan;73(1):347-52. doi: 10.1128/AEM.01616-06. Epub 2006 Nov 3.
引用本文的文献
1
[Phage endolysins-a novel class of antibacterial agents with a wide range of applications].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 May 6. doi: 10.1007/s00103-025-04059-9.
2
Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications.
Infect Dis Ther. 2025 Jan;14(1):13-57. doi: 10.1007/s40121-024-01069-z. Epub 2024 Nov 16.
3
The Synergistic and Chimeric Mechanism of Bacteriophage Endolysins: Opportunities for Application in Biotherapeutics, Food, and Health Sectors.
Probiotics Antimicrob Proteins. 2025 Apr;17(2):807-831. doi: 10.1007/s12602-024-10394-1. Epub 2024 Nov 7.
4
Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria.
J Biomed Sci. 2023 Apr 26;30(1):29. doi: 10.1186/s12929-023-00919-1.
5
Influence of NaCl and pH on lysostaphin catalytic activity, cell binding, and bacteriolytic activity.
Appl Microbiol Biotechnol. 2022 Oct;106(19-20):6519-6534. doi: 10.1007/s00253-022-12173-w. Epub 2022 Sep 16.
6
Exploration of Bacterial Re-Growth as In Vitro Phenomenon Affecting Methods for Analysis of the Antimicrobial Activity of Chimeric Bacteriophage Endolysins.
Microorganisms. 2022 Feb 15;10(2):445. doi: 10.3390/microorganisms10020445.
7
Development of a Novel Chimeric Endolysin, Lys109 With Enhanced Lytic Activity Against .
Front Microbiol. 2021 Jan 15;11:615887. doi: 10.3389/fmicb.2020.615887. eCollection 2020.
8
Characterization of Clinical MRSA Isolates from Northern Spain and Assessment of Their Susceptibility to Phage-Derived Antimicrobials.
Antibiotics (Basel). 2020 Jul 25;9(8):447. doi: 10.3390/antibiotics9080447.
9
LytU-SH3b fusion protein as a novel and efficient enzybiotic against methicillin-resistant .
Mol Biol Res Commun. 2019 Dec;8(4):151-158.
10
Phage Endolysins as Potential Antimicrobials against Multidrug Resistant and : Current Status of Research and Challenges Ahead.
Microorganisms. 2019 Mar 18;7(3):84. doi: 10.3390/microorganisms7030084.
本文引用的文献
1
Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.
Antimicrob Agents Chemother. 2011 Apr;55(4):1764-7. doi: 10.1128/AAC.01097-10. Epub 2011 Jan 24.
2
Inhibition of the activity of both domains of lysostaphin through peptidoglycan modification by the lysostaphin immunity protein.
Appl Environ Microbiol. 2010 Oct;76(20):6944-6. doi: 10.1128/AEM.01066-10. Epub 2010 Aug 20.
3
Bacteriophage-resistant Staphylococcus aureus mutant confers broad immunity against staphylococcal infection in mice.
PLoS One. 2010 Jul 22;5(7):e11720. doi: 10.1371/journal.pone.0011720.
4
Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens.
Int J Med Microbiol. 2010 Aug;300(6):357-62. doi: 10.1016/j.ijmm.2010.04.002. Epub 2010 May 10.
5
A poke into the diversity and associations within human anterior nare microbial communities.
ISME J. 2010 Jul;4(7):839-51. doi: 10.1038/ismej.2010.15. Epub 2010 Feb 25.
6
Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
Diagn Microbiol Infect Dis. 2009 Dec;65(4):404-13. doi: 10.1016/j.diagmicrobio.2009.10.001.
7
Mupirocin resistance.
Clin Infect Dis. 2009 Sep 15;49(6):935-41. doi: 10.1086/605495.
8
Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects.
J Antimicrob Chemother. 2009 Jul;64(1):9-15. doi: 10.1093/jac/dkp159. Epub 2009 May 18.
9
Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review.
Clin Infect Dis. 2009 Apr 1;48(7):922-30. doi: 10.1086/597291.
10
Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers.
Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD006216. doi: 10.1002/14651858.CD006216.pub2.
Zotero 插件